Board of Directors

Mr Annexstad is a co-founder of NorgesInvestor AS, an Oslo-based investment and private equity firm. He has senior industry experience, both at executive and Board levels. He was the CEO of the pharmaceutical firm Nycomed AS (subsequently merged with Amersham Plc and thereafter acquired by GE) and is also the former deputy CEO of Hafslund Nycomed AS (the parent company of Nycomed, following an acquisition). He is also a former executive of Dyno Industrier AS (fine chemicals) and head of AS ISCO Group, an executive search and corporate advisory group. Mr Annexstad holds a BA in Commerce from the Norwegian School of Economics (1969). He is currently Chairman of the Board at Investinor AS, the VC of the Norwegian State. Previous Chairman positions comprise banking, business school, public R&D, and various industries. Mr Annexstad joined the Board of Algeta in October 2000.

As of 11 April 2013, Mr Annexstad holds 61,290 shares and 20,000 share options in Algeta.

Mr Annexstad took part in 23 out of 25 Board meetings in 2012.

Mr Berriman is the Chairman of Heptares Therapeutics Ltd and Autifony Therapeutics Ltd and a member of the Board of Directors of ReNeuron Group Plc (RENE.L) and Cytos AG (CYTN.SW). Until its sale to Amgen in the spring of 2012, he was also a Director of MicroMet Inc. (MITI.NASDAQ). Previously, he was a Director of Abingworth Management Ltd, the international life sciences and healthcare investment group, at which he was involved in founding, financing, and serving as a Director of several biotechnology companies in Europe and the US – many of which obtained listings on public stock exchanges. Prior to that, Mr Berriman spent 14 years with Celltech Group Plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from London Business School. Mr Berriman joined the Board of Algeta in 2004.

As of 11 April 2013, Mr Berriman holds 90,000 shares and 44,000 share options in Algeta.

Mr Berriman took part in 23 out of 25 Board meetings in 2012.

Dr Dhingra is the Managing Member of KAPital Consulting, LLC, a consulting company dedicated to assisting biotechnology, pharmaceutical, and diagnostic companies realize the full potential of clinical and commercial advances in oncology. He currently serves on the Board of Directors of Exosome Diagnostics and YM Biosciences. He is a member of the External Scientific Advisory Council of Institute Gustave Roussy and a member of the New Drug Advisory Committee of the EORTC. He also serves on the NCI Experimental Therapeutics Special Emphasis Panel, the Scientific Advisory Board of the Avon Foundation, and the Commercialization Review Committee of the Cancer Prevention and Research Institute of Texas. He has more than 25 years of experience in oncology clinical and translational research and drug development. From 1999 to 2008, Dr Dhingra worked in positions of increasing responsibility at Hoffmann-La Roche, most recently serving as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to Hoffmann-La Roche, from 1996 to 1999, Dr Dhingra worked as a Clinical Research Physician with Eli Lilly and Company; and from 1989 to 1996, as a Clinical Instructor, Assistant Professor of Medicine at the University of Texas MD Anderson Cancer Center. Throughout his industry career, he maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor, and, more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Dr Dhingra holds an MBBS degree (equivalent to a US MD degree) from the All India Institute of Medical Services and has performed postgraduate work at the All India Institute of Medical Services, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx, NY, and Emory University School of Medicine, Atlanta, GA. Dr Dhingra joined the Board of Algeta in April 2010.

As of 11 April 2013, Dr Dhingra holds no shares and 24,000 share options in Algeta.

Dr Dhingra took part in 22 out of 25 Board meetings in 2012.

Dr Hemberger is an experienced biotech industry executive with more than 30 years of global pharmaceutical and biotech industry experience. Dr Hemberger was a co-founder, Executive Vice President, and Chief Operating Officer of Pharmion Corporation from its inception in 2000 until 2006. Prior to that, she served as Senior Vice President of Business Development at AVA X Technologies, Inc., a vaccine technology company. From 1979 to 1998, Dr Hemberger worked in various capacities at Marion Laboratories, a pharmaceutical company, and its successor companies Marion Merrell Dow and Hoechst Marion Roussel, where she led a number of strategic functions including Professional Education, Global Regulatory Affairs, Global Medical Affairs, and Commercial Development. Her final role at Hoechst Marion Roussel was Senior Vice President of Global Drug Regulatory Affairs. More recently, Dr Hemberger was a Venture Partner at Nomura Phase4 Ventures (2006-2009) and Interim CEO of Zosano Pharma, Inc. Dr Hemberger is the Chairman and CEO of SuviCa Inc. and the Chairman of Clarimedix. In addition, she currently serves on the Board of Directors of VasoGenix Pharmaceuticals, Inc. and has previous Board experience with Marion Merrell Dow, NexStar Pharmaceuticals, Cell Pathways, Schein, Pharmion, PRA International, Perrigo, Renovis, Myogen, Zosano Pharma, Novacea, Health Shares, Zymogenetics, and Atani. Dr Hemberger received a BS in Biology and Chemistry from Mount St Scholastica College (St Benedictine College), a PhD in Pharmacology from the University of Missouri-Kansas City, and an MBA from Rockhurst College. Dr Hemberger joined the Board of Algeta in April 2010.

As of 11 April 2013, Dr Hemberger holds 8,640 shares and 24,561 share options in Algeta.

Dr Hemberger took part in 22 out of 25 Board meetings in 2012.

Mr Samuelsson is a Partner at Odlander Fredrikson/HealthCap, the life sciences venture capital firm, which he joined in 2000. Prior to this, he gained more than 15 years of investment banking experience, mainly with Aros Securities in Sweden. In his final position with Aros Securities, as a Director in the firm’s corporate finance department, he specialized in the areas of merger transactions, initial public offerings, and equity incentive programs. Prior to this, Mr Samuelsson was Head of Research, also at Aros Securities. He currently holds several Board positions at BioStratum Inc, Cardoz AB, Nordic Vision Clinics AS, Oncos Therapeutics Oy, Oncopeptides AB, SwedenBIO, and Topotarget A/S. Mr Samuelsson received his MSc in Engineering from the Institute of Technology in Linköping. Mr Samuelsson joined the Board of Algeta in September 2005.

As of 11 April 2013, Mr Samuelsson holds no shares and no share options in Algeta.

Mr Samuelsson took part in 23 out of 25 Board meetings in 2012.

Dr Steineger is VP Business Development at Pronova BioPharma ASA (listed on the Oslo Stock Exchange), a global leader in the research, development, and manufacture of marine-originated omega-3-derived pharmaceutical products. Previously, Dr Steineger was VP Investor Relations & Communications at Pronova BioPharma, and prior to that she was Senior Associate with Neomed Management, an international investment firm focusing on the healthcare and life science industry. From 2004 to 2006, she worked as an independent advisor focusing on start-ups within the life science/health care sector, and before that she was an equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen (2001-2004). Dr Steineger began her professional career at Nycomed Pharma, where she worked in the area of clinical research and international marketing from 1999 to 2001. Dr Steineger is a member of the Board of Directors at Clavis Pharma ASA, Weifa AS, and Inven2 AS. She holds a BSc and a PhD in Medical Biochemistry from the University of Oslo. Dr Steineger joined the Board of Algeta in December 2007.

As of 11 April 2013, Dr Steineger holds no shares and 25,611 share options in Algeta.

Dr Steineger took part in 24 out of 25 Board meetings in 2012.

Paolo Pucci is Chief Executive Officer and member of the Board of Directors of ArQule Inc., a US-based, Nasdaq-listed cancer therapeutics company, which he joined in 2008. Before this, Mr Pucci was at Bayer AG, where he held sequential responsibilities as Country Head Bayer Italy Pharmaceuticals, President & SVP Bayer Pharmaceuticals North America – Global Specialty Pharmaceuticals, and member of the Bayer Pharmaceuticals Executive Committee. He concluded his tenure at Bayer as President in charge of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Units and was instrumental in building Bayer’s global oncology franchise for Nexavar®. Prior to this, Mr Pucci held positions of increasing responsibility with Eli Lilly between 1991 and 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr Pucci is Non-executive Director on the Board of Dyax, Inc. Mr Pucci holds an MBA from the University of Chicago and is a graduate of the Universita Degli Studi Di Napoli in Naples, Italy. Mr Pucci is an Italian citizen and resides in Boston, MA, USA. Mr Pucci joined the Board of Algeta in April 2013.

As of 11 April 2013, Mr Pucci holds no shares and 8,000 options in Algeta.

Hilde Furberg has 30 years of experience in the pharmaceutical industry. She is currently Senior Vice President RD (Rare Disease) EMEA at Genzyme (Sanofi), which she joined in 2002. She opened the first operation for Genzyme in the Nordic region and has also had management responsibility for Genzyme in the BeneLux region. Prior to Genzyme, Mrs Furberg spent 19 years at Baxter and Pharmalink in various business roles of increasing seniority. She is a Non-executive Director on the Board of Clavis Pharma ASA and is a board member of Copenhagen Capacity. Previous board memberships include Probi AB and Pronova Biopharma ASA (part of BASF).
Mrs Furberg holds a Master of Science degree in Nuclear Analytical Chemistry from the University of Oslo. She is a Norwegian citizen and resides in de Naarden, Netherlands. Mrs Furberg joined the Board of Algeta in April 2013.

As of 11 April 2013, Mrs Furberg holds 2,000 shares and 8,000 options in Algeta ASA.